Portable electrochemical assay system for on chip quantitative estimation of bla...
Portable electrochemical assay system for on chip quantitative estimation of bladder cancer biomarkers in real samples
Cancer is a leading cause of death worldwide and the best approaches to improve cancer survival rate is to diagnose it at an early stage. In spite of the rapid explosion of new technology platforms, traditional optical ELISA is us...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PDC2021-121444-I00
BIOSENSOR PARA MONITORIZACION DE BIOMARCADORES DE CANCER COL...
86K€
Cerrado
uQuantEV
Microfluidic EV Quantification for Point-of-Care CRC diagnos...
165K€
Cerrado
BLACANDI
BLACANDI can improve life quality and cut cost of diagnosing...
71K€
Cerrado
CTQ2015-63567-R
SELECCION Y MODIFICACION DE APTAMEROS COMO RECEPTORES ESPECI...
90K€
Cerrado
BIO2011-30535-C04-03
SEPARACION ACUSTICA DE CELULAS TUMORALES EN SANGRE CON CHIPS...
80K€
Cerrado
RTC-2015-4167-1
DESARROLLO DE UNA PLATAFORMA COMPLETA PARA EL ANÁLISIS DE CÉ...
849K€
Cerrado
Información proyecto BlaC E-assay
Duración del proyecto: 30 meses
Fecha Inicio: 2015-03-13
Fecha Fin: 2017-10-04
Líder del proyecto
UNIVERSITY OF BATH
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
195K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Cancer is a leading cause of death worldwide and the best approaches to improve cancer survival rate is to diagnose it at an early stage. In spite of the rapid explosion of new technology platforms, traditional optical ELISA is used in clinical practice, which is laborious, time-consuming, require large sample volume and suffer from low sensitivity. On the other hand, recently proposed electrochemical sensors which promise easy operation, accuracy, high sensitivity, low cost and compact size mainly suffer from background signals, non-specificity and selectivity in clinical samples. Therefore, there is an urgent need to solve the key issues in the development of clinically relevant and commercially viable technologies that enable screening of high-risk individuals for cancer at an early stage. The proposed program is to develop a reliable point-of-care (POC) diagnostic system based on a multidisciplinary approach of integrated microfluidic and electrochemistry for multiple biomarker detection in clinical samples. The proposal aims at finding solutions for key issues of non-specificity, sensitivity and selectivity in clinical samples for sensitive and multiplexed detection. The proposal will address the above mentioned challenges, via separation of assay chamber and detection chamber with innovative surface chemistry and microfluidic design with electrochemical detection techniques. Work will be focused on bladder cancer as a test model to solve the above mentioned issues. The proposed device will be of bench top size and have capabilities to detect a panel of 3 or more biomarkers simultaneously. The successful outcome of the project will result in high impact publications, technology know-how and IP, which will be used to design and develop a prototype device. A secondment at Applied Enzyme Technology Ltd, Gwent Group (GWENT) will be used to study optimization of sensor shelf life and to ensure the developed system meets industrial standards.